What's the Problem?

The selection of the most appropriate therapy for a cancer patient is based on population meta-analyses that do not guarantee the individual response of each patient. Precision Oncology seeks to identify predictive biomarkers, mainly of the genomic type, that help assign targeted therapies with greater chances of therapeutic success. Unfortunately, these therapies only benefit a small group of cancer patients (~15% qualify for genome-targeted therapies and only around 8% of patients respond favorably). Therefore, clinicians continue to prescribe therapy using the Standard of Care and a trial-and-error dosing approach, which results in a large percentage of patients not responding positively and billions of dollars spent on treatments that ultimately fail.

How are they Solving it?

OncoPrecision has developed a proprietary ex-vivo functional assay to attempt to predict cancer patients’ potential sensitivity or resistance to cancer therapies and thus help clinicians tailor their treatment. OncoPrecision’s platform utilizes patient-derived cells, which are co-cultured with proprietary cell lines that help mimic the patient’s tumor microenvironment, which are dosed with drugs and drug combinations to analyze their response within 7 days. The goal is to provide clinicians with actionable and easy to interpret data, with the potential of improving patient outcomes and Pharma Companies with key insights to optimize drug development efforts. OncoPrecision is initially focusing on leukemia for its MVP, with the goal of expanding its technology to solid tumors in the near future.

Go to their website

Next Startup

Puna Bio

Go back to portfolio